The Aurora A kinase inhibitor (AURKAi) LSN3321213 combined with the PD-L1 inhibitors, achieved persistent anti-tumor efficacy in the immunocompetent SCLC genetically engineered mouse models (GEMMs) and syngeneic xenografts: LSN3321213 arrested tumor cells in the mitotic phase (M phase), restored interferon signal transduction, increased the sensitivity of tumor cells to PD-L1 inhibitor; simultaneously, it induced high interferon signaling and MHC-I, promoting CD8+ T cell-mediated tumor cell killing (157). Here, AURKA is linked to small cell lung carcinoma.